UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): January 10, 2008

 

DexCom, Inc.

(Exact Name of the Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

000-51222

 

33-0857544

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

5555 Oberlin Drive, San Diego, CA

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

(858) 200-0200

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, If Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2)

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

Item 7.01:  Regulation FD Disclosure.

 

On Thursday, January 10, 2008, DexCom, Inc. (“DexCom”) issued a press release announcing that it has entered into a joint development agreement with Animas Corporation (“Animas”) to integrate DexCom’s continuous glucose monitoring technology into Animas insulin pumps. A copy of the press release is attached to this report as Exhibit 99.01.

 

Item 9.01:  Financial Statements and Exhibits.

 

(d)  Exhibits

 

Exhibit
Number

 

Description of Exhibit

 

 

 

99.01

 

Press release dated January 10, 2008 regarding DexCom’s entry into a joint development agreement with Animas Corporation.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

DEXCOM, INC.

 

 

 

By:

 

/s/ Steven R. Pacelli

 

 

 

Steven R. Pacelli

 

 

Senior Vice President of Corporate Affairs

 

 

Date:  January 10, 2008

 

3



 

EXHIBIT INDEX

 

Exhibit
Number

 

Description of Exhibit

 

 

 

99.01

 

Press release dated January 10, 2008 regarding DexCom’s entry into a joint development agreement with Animas Corporation.

 

4